• Canagliflozin and Renal Mitochondrial Remodeling

  2026-10-07

  A 2025 study reports that Canagliflozin altered proximal tubular cell mitochondrial structure and bioenergetics in hypertensive–diabetic mice, with stronger functional effects in males than females. The findings extend interpretation of SGLT2 inhibitor kidney protection beyond renal glucose reabsorption inhibition, while remaining limited to a short-term preclinical model.

• Isochlorogenic Acid A Hydrogel: Study Findings

  2026-10-07

  A 2026 Gels study developed a composite wound dressing by co-assembling Isochlorogenic acid A with Fe(III) nanoparticles and embedding them in an amylopectin/carboxymethyl chitosan hydrogel. The reported formulation combined antibacterial activity, self-healing and adhesive properties, support for cell migration, inflammatory-marker modulation, and improved wound closure in a preclinical model, while remaining limited by the study’s specific formulation and evidence scope.

• Isochlorogenic Acid A: Evidence in Wound Repair

  2026-10-06

  Isochlorogenic acid A, also called 3,5-dicaffeoylquinic acid, is a plant-derived polyphenol being investigated in natural product, anti-infection, inflammation, and biomaterials research. The strongest supplied evidence is a 2026 preclinical study of an amylopectin/carboxymethyl chitosan hydrogel containing Isochlorogenic acid A/Fe(III) co-assembled nanoparticles. The reported results are promising but apply primarily to the complete formulation, not to the isolated compound alone. This overview separates published findings from interpretation and explains the study’s translational limits.

• Repaglinide and Metabolic Signaling in AML Research

  2026-10-06

  Repaglinide offers a useful entry point for discussing how metabolic state may intersect with DNA repair in cancer research. This article interprets the ATG4B–PRMT1–MRE11 mechanism reported in AML while separating established findings from hypotheses that require validation.

• Demethyleneberberine: Mechanism to Translation

  2026-10-05

  Demethyleneberberine is best understood as a multi-pathway research hypothesis rather than a clinically validated therapy. This evidence-led perspective examines its autoimmune hepatitis findings, broader translational opportunities, competitive positioning, and the limitations that should shape future validation.

• Exendin-4: Reading GLP-1 Evidence Clearly

  2026-10-05

  Exendin-4, also known as Exenatide, is more than a beta cell stimulus: it is a useful lens for separating receptor pharmacology, metabolic phenotypes, and manufacturing evidence. This article examines how to interpret findings across models without overstating translational relevance.

• Canagliflozin Remodels Mitochondria in Diabetic Kidneys

  2026-10-04

  A 2025 mouse study links Canagliflozin treatment with structural and bioenergetic changes in proximal tubular cell mitochondria in a hypertensive–diabetic model. Its findings suggest that the renal effects of SGLT2 inhibition may involve mitochondrial remodeling beyond glucose lowering, although sex differences and the preclinical design limit broad clinical interpretation.

• Toremifene in Prostate Cancer Research: Evidence Overview

  2026-10-03

  This source-grounded overview examines Toremifene as a selective estrogen-receptor modulator in prostate cancer research, alongside evidence on the TSPAN18–STIM1 calcium-signaling axis and bone metastasis. It distinguishes supplier-reported activity from peer-reviewed findings, outlines conceptual research applications, and explains why current evidence does not establish that Toremifene directly inhibits or modulates the TSPAN18–STIM1 pathway.

• Dantrolene Sodium Salt: A Translational RyR Strategy

  2026-10-02

  Dantrolene sodium salt offers a mechanistically defined way to interrogate ryanodine receptor activity, calcium homeostasis, and disease-relevant cell stress. This article connects established RyR biology with a cautious, testable framework for pancreatitis, ischemia and hypoxia research, neurodegenerative disease models, and exploratory CRISPR repair studies.

• Dextrose (D-glucose) in Tumor Metabolism

  2026-10-01

  Use Dextrose (D-glucose) as a controlled metabolic variable for modeling nutrient competition, hypoxia, and immune dysfunction in tumor systems. This workflow combines concentration-matched media, oxygen-defined exposures, and troubleshooting guidance for more reproducible glucose metabolism research.

• AP20187 and the Logic of Programmable Tumor Stroma

  2026-10-01

  Senescent cancer-associated fibroblasts can suppress natural killer cell activity and promote breast cancer progression. This thought-leadership analysis examines how AP20187, a chemical inducer of dimerization, could help translational researchers build conditional systems to test stromal, immune, and metabolic mechanisms without confusing experimental control with clinical readiness.

• Sitagliptin Phosphate Monohydrate in Gut–Brain Assays

  2026-09-30

  Sitagliptin phosphate monohydrate is a selective DPP-4 inhibitor for dissecting incretin biology and glucose regulation. This article translates new intestinal-stretch findings into practical assay controls that separate GLP-1-dependent effects from mechanical gut–brain signaling.

• Berberine Hydrochloride: Mechanisms & Workflows

  2026-09-30

  Berberine hydrochloride is an isoquinoline alkaloid reagent used in metabolic, lipid, cancer, and inflammation research. Its documented AMPK, LDLR, apoptosis, and formulation properties support controlled bench workflows, while the cited acute kidney injury study provides an inflammation framework rather than direct evidence for berberine treatment.

• Taihangia rupestris: UPLC-MS/MS and Bioactivity

  2026-09-29

  A 2026 RSC Advances study integrated UPLC-MS/MS, complementary antioxidant assays, α-glucosidase inhibition, affinity screening, and molecular docking to compare wild and cultivated Taihangia rupestris leaves. The results identify foothill cultivation as a promising, conservation-compatible source of flavonoid- and phenolic-associated bioactivity, while also showing why DPPH should be interpreted alongside orthogonal chemical and enzymatic measurements.

• Cimetidine at the BBB: Assay Logic for Cancer Research

  2026-09-29

  Cimetidine research benefits from separating H2 receptor biology from transport and intracellular sequestration. This guide applies a validated surrogate blood-brain barrier framework to assay design, solubility control, and translational cancer research decisions.

8185 records 1/546 page Next 12345 下5页 Last page